BioStock: Lipum is looking forward to the new year

2021 was an eventful year for Lipum with several achieved milestones in the preparation for the first clinical trial with the biological drug candidate SOL-116 for the treatment of chronic inflammatory diseases. Another significant milestone during the year was, of course, the listing on Nasdaq First North Growth Market. Lipum is now looking forward to 2022 when the company enters the clinical stage, which CEO Einar Pontén tells us more about in an interview with BioStock.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/01/lipum-is-looking-forward-to-the-new-year/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se